KRAS and pancreatic ductal adenocarcinoma: Although KRAS and TP53 alterations can be associated with pancreatic ductal adenocarcinoma, collectively the genomic profile, as well as the histopathologic findings (Fig. 2) were consistent with a bona fide high grade PDNEC harboring homologous recombination deficiency.